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A B S T R A C T
Alzheimer’s disease (AD), which accounts for most of the dementia cases, is, aside from cognitive deterioration,
often characterized by the presence of non-cognitive symptoms such as activity and sleep disturbances. AD
patients typically experience increased sleep fragmentation, excessive daytime sleepiness and night-time in-
somnia. Here, we sought to investigate the link between sleep architecture, cognition and amyloid pathology in
the APP23 amyloidosis mouse model for AD. By means of polysomnographic recordings the sleep-wake cycle of
freely-moving APP23 and wild-type (WT) littermates of 3, 6 and 12 months of age was examined. In addition,
ambulatory cage activity was assessed by interruption of infrared beams surrounding the home cage. To assess
visuo-spatial learning and memory a hidden-platform Morris-type Water Maze (MWM) experiment was per-
formed. We found that sleep architecture is only slightly altered at early stages of pathology, but significantly
deteriorates from 12 months of age, when amyloid plaques become diffusely present. APP23 mice of 12 months
old had quantitative reductions of NREM and REM sleep and were more awake during the dark phase compared
to WT littermates. These findings were confirmed by increased ambulatory cage activity during that phase of the
light-dark cycle. No quantitative differences in sleep parameters were observed during the light phase. However,
during this light phase, the sleep pattern of APP23 mice was more fragmented from 6 months of age, the point at
which also cognitive abilities started to be affected in the MWM. Sleep time also positively correlated with MWM
performance. We also found that spectral components in the EEG started to alter at the age of 6 months. To
conclude, our results indicate that sleep architectural changes arise around the time the first amyloid plaques
start to form and cognitive deterioration becomes apparent. These changes start subtle, but gradually worsen
with age, adequately mimicking the clinical condition.
1. Introduction
World’s leading cause of dementia, Alzheimer’s disease (AD), is a
progressive, neurodegenerative disorder affecting an increasing aged
population. Apart from the characteristic cognitive decline, up to 60%
of AD patients experience sleep and circadian rhythm disturbances
[1,2]. Compared to healthy aging, AD is associated with increased sleep
fragmentation, excessive daytime sleepiness and night-time insomnia
[3–7]. Non-rapid eye movement (NREM) and rapid eye movement
(REM) sleep are quantitatively reduced, resulting in a reduced total
sleep time (TST) [6]. Moreover, the deepest stages of NREM sleep, also
referred to as slow wave sleep (SWS), are often absent [6], resulting in a
diminished sleep efficiency. Additionally, circadian dysrhythmia might
lead to the emergence of the ‘sundowning’ phenomenon, which can
ultimately lead to a complete reversal of the day-night cycle in these
patients. Sleep disorders and sundowning decrease the self-care ability
of AD patients, are among the main reasons for caregiver exhaustion,
and greatly impact the rate of institutionalization [8,9].
Sleep and circadian rhythm disturbances already occur in early
stages of probable AD and parallel the progressive cognitive decline
[8,10]. Sleep abnormalities are often considered to be a consequence of
AD pathology [11–13]. However, sleep is important to remove toxic
proteins and peptides from the brain [14]. Accordingly, studies have
demonstrated that sleep loss can increase interstitial fluid amyloid-beta
(Aβ) and, consequently, plaque burden [15]. Therefore, it is suggested
that amyloid plaque formation alters Aβ dynamics, resulting in a dis-
turbed sleep-wake cycle, thereby exacerbating the accumulation of
toxic proteins and the progression of the pathology [16]. Moreover,
sleep processes are presumed to participate in memory consolidation,
an active process that relies on reactivation and reorganization of newly
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encoded representations [17]. Disruption of sleep interferes with cog-
nitive abilities, even in healthy young people [18]. Thus, extensively
reduced amounts of sleep will aggravate cognitive decline in AD even
more.
The APP23 amyloidosis mouse model has already been thoroughly
characterized and mimics many clinical AD symptoms [19]. Hemi-
zygous (HEM) APP23 display scarce Aβ deposits from 6 months of age.
They increase in size and number with aging, until an extensive area of
the neocortex and hippocampus is occupied by amyloid deposits at 24
months of age. Moreover, amyloid deposits in cerebral vasculature, also
known as cerebral amyloid angiopathy, start to form from 9 months of
age and increase with age [19–21]. Here, we aimed to further under-
stand the contribution of amyloid pathology to sleep regulation and
circadian function, and its influence on acquisition and retrieval of
memory in AD. We, therefore, established whether APP23 mice display
age-related disruptions in baseline sleep architecture and circadian
distribution of sleep and activity. Furthermore, we examined whether
these changes correlate with spatial learning and memory capacities
and spectral components in the electroencephalogram (EEG).
2. Materials and methods
2.1. Animal model
The transgenic APP23 amyloidosis mouse model of AD carries the
human APP gene containing the Swedish mutation (KM670/671 N L) on
a C57BL/6 J background. The expression is under control of the murine
neuronal Thy1 promotor [21], which results in approximately tenfold
overexpression of APP in the hippocampus of HEM vs wild-type (WT)
controls. In addition, the cortical APP expression steadily increments
with age, with a 2-fold overexpression at 6–8 weeks and 20-fold over-
expression at 24 months [22]. Male, HEM APP23 mice and their WT
littermates of 3 (WT: n=10, HEM: n=11), 6 (WT: n=12, HEM:
n=10) and 12 (WT: n=11, HEM: n=11) months of age were bred
and aged in our facilities. The amyloid load of these mice increases with
age, with no amyloid deposition at 3 months and extensive amyloid
plaques at 12 months of age. All mice were group-housed in standard
mouse cages under conventional laboratory conditions, and in-
dividually housed from the day of electrode implantation; constant
room temperature (22 ± 2 °C), humidity level (55 ± 5%), 12 h/12 h
day/night cycle (lights on at 8 a.m.). Food and water were supplied ad
libitum. Custom primers (Biolegio, The Netherlands) were used for
genotyping by PCR analysis performed, on DNA extracted from ear
punches, collected from mice aged 4 weeks. All experiments were
carried out in compliance with the European Community Council Di-
rective (2010/63/EU) and were approved by the Animal Ethics Com-
mittee of the University of Antwerp (ECD approval n° 2011/49).
2.2. Video EEG recording
By stereotactic surgery, two active screw EEG electrodes (E363/96/
1.6, Plastics One Inc., Roanoke, USA) were implanted over the frontal
and parietal cortices, while one ground and one reference electrode
were placed over the cerebellum (coordinates from reference point
Bregma: right frontal cortex: anteroposterior (AP) +2.0 mm, mediolateral
(ML) +2.0 mm; right parietal cortex: AP – 2.0 mm, ML +2.0 mm; ground
electrode: AP – 4.90 mm, ML 0.0 mm; reference electrode: AP – 6.70mm,
ML 0.0 mm) [23]. Two EMG electrodes (E363/76/SPC, Plastics One
Inc., Roanoke, USA) were inserted into the nuchal muscles. All im-
planted electrodes were fixed to the skull with carboxylate cement
(Durelon™, 3 M ESPE S.A., Germany). The sockets were attached to an
electrode pedestal (MS 363, Plastics One, Roanoke, V.S.) and the as-
sembly was secured to the skull by carboxylate cement (Durelon™, 3 M
ESPE S.A., Germany). Postoperatively, animals were housed in-
dividually and carefully monitored for pain and distress.
After a seven-day recovery period, video EEG of freely-moving
APP23 and WT mice commenced with three days of habituation in the
EEG recording room. Then, baseline EEG was recorded with a 40-
channel EEG headbox (Large EEG headbox, Schwarzer Ahns, Germany)
for 72 h, of which only the last 24 h were included into the sleep ana-
lysis. Additionally, the experiment was recorded with a video camera
(DCR-DVD105 DVD Handycam camcorder with 20x optical zoom and
infrared lens, Sony). Via a video converter (Canopus ADVC55), the
analog signal was digitally converted. In the BrainRT™ software the
video was synchronized with the recorded EEG. The video was used to
check for abnormalities during the recordings and to assist during
vigilance scoring. The EEG signal was sampled at a rate of 250 Hz and
band-pass filtered between 0.5 and 30 Hz. Scoring of sleep stages was
performed manually and off-line in 4-s epochs by visual inspection of
the raw EEG an EMG signal in BrainRT™ (OSG BVBA, Rumst, Belgium).
In our experience, automated sleep scoring is around 20% less accurate
than manual scoring and therefore the latter was preferred. The vigi-
lance states were defined as follows: (1) wake (EEG with low amplitude
(A), high frequency (f) EEG; high EMG activity), (2) NREM (EEG with
high A, low f; low EMG activity), (3) REM (EEG with low A, high f; low
EMG activity) [24]. The minimal interruption criteria were applied to
determine the vigilance state episodes as previously described [25,26].
The individual sleep parameters were calculated for both the light and
dark phase. Sleep fragmentation was defined as the number of brief
awakenings (i.e. waking episodes shorter than 16 s).
The 24 -h scored EEG signals were downsampled to 125 Hz and
subjected to Fast Fourier transform (FFT) in BrainRT™ to generate delta
(0.5–3.5 Hz), theta (3.5–7.5 Hz), alpha (7.5–12.5 Hz) and beta
(12.5–30 Hz) band power in wake, NREM and REM. These frequency
ranges are routinely applied in a (pre)clinical setting [27–29]. A four-
second epoch window (that corresponded with the sleep scoring
window) with Hanning filter and FFT size of 512 was used. Power was
calculated from 0 to 62.5 Hz with a 0.244 Hz bin width. Power was
expressed relatively to the sum of all band power values (%), to mini-
mize variations in oscillatory amplitude between animals.
2.3. Ambulatory cage activity
Horizontal locomotor activity was tracked in the EEG recording
chamber using three infrared sensors. The number of beam crossings
was counted in 4 s bins.
2.4. Morris water maze
Three days after polysomnography, evaluation of spatial learning
and memory was initiated by means of the hidden platform Morris
Water Maze (MWM) test [30]. In this experimental setup, a circular
pool (diameter: 150 cm, height: 30 cm) was filled with opacified water,
kept at 25 °C, in which a Perspex platform (diameter 15 cm) was placed
in one of the quadrants. The water surface is 1 cm above the platform
and the MWM is surrounded by invariable visual cues. Acquisition
training consisted of eight trial blocks (during two weeks) of four daily
trials starting from four different positions in a quasi-random order with
a 15-min intertrial interval. During the first week of the MWM, all mice
underwent 4 consecutive trial blocks, one trial block each day. After a
3-day interval, again 4 consecutive trial blocks were performed during
week two. During these training trials the escape latency to the plat-
form, path length and swim speed was measured using a computerized
video-tracking system ((Ethovision 6, Noldus, Wageningen, the Neth-
erlands). If a mouse was not able to reach the platform within 120 s, it
was placed on the platform, where it stayed for 15 s before being re-
turned to its home cage. Four days after the last trial block, the ac-
quisition phase was followed by a probe trial, in which the platform was
removed from the maze, and in which the animals were allowed to
swim freely for 100 s. Probe trial performance is expressed as the per-
centage of time spent in each quadrant of the MWM.
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2.5. Statistics
Baseline polysomnographic recordings and MWM acquisition data
were analyzed using mixed design ANOVA. Genotype differences per
age group were further assessed with Student’s t-test. Similarly, mixed
design ANOVA was used to analyze ambulatory cage activity. Then,
phase differences were assessed with paired samples t-test and genotype
differences with independent samples t-test. Spectral genotype-related
differences in the EEG were assessed using independent samples t-test
for every separate vigilance parameter. ANOVA with post-hoc
Bonferroni correction was used to identify age differences in fronto-
parietal ratio parameters, while independent samples t-tests served to
identify differences between genotypes. All statistical results were
considered significant for a value of p < 0.05, unless stated otherwise.
Statistical calculations were performed using SPSS 24 (IBM, SPSS Inc.,
Chicago, IL, USA).
3. Results
3.1. Hippocampus-dependent learning was affected from 6 months of age
An overall mixed design ANOVA revealed an overall gradual de-
crease in path length (F(7, 413)= 50.329 ; p= .000) and latency (F(7,
413)= 92.671 ; p= .000) over all eight acquisition trials, demon-
strating an appropriate learning curve for all animals. Also, the statis-
tical model showed that for both path length and escape latency there
was an effect of age (path length: F(2, 59)= 3.222 ; p= .047; escape
latency: F(2, 59)= 7.731; p= .001), genotype (path length: F(1,
59)= 18.212 ; p= .000; escape latency: F(1, 59)= 20.261; p= .000)
as well as an interaction effect between age and genotype (path length:
F(2, 59)= 3.497 ; p= .037; escape latency: F(2, 59)= 3.445; p=
.038). Velocity was affected by age (F(2, 59)= 10.715; p= .000) but
not by genotype (F(1, 59)= 0.609; p= .438). To reduce the com-
plexity of the data, genotype and trial effects were assessed by applying
a mixed model per age group.
Genotype had no effect on path length (F(1, 19)= 0.068; p= .797)
and escape latency (F(1, 19)= 0.187; p= .670) in 3-month-old ani-
mals. In addition, the profile of their learning curve was not sig-
nificantly different between the different genotypes, since the interac-
tion between trial and genotype was statistically non-significant (p=
.403). Thus, young WT and HEM APP23 mice performed similarly in
the MWM (Fig. 1).
At 6 months of age, APP23 mice swam a significantly longer dis-
tance (Fig. 1) and needed a significantly longer escape latency to reach
the platform (Fig. 1) when compared to WT mice of the same age.
Mixed design ANOVA revealed a significant effect of genotype on path
length (F(1, 20)= 13.852; p = .001) and on escape latency (F(1,
20)= 11.076; p = .003). Moreover, the interaction of genotype with
the different trials significantly influenced path length (F(4.3,
86.9)= 3.271; p = .013), but not escape latency (F(4.075,
81.5)= 1.989; p = .103). The genotype-related differences cannot be
explained by a difference in swimming speed since the statistical model
showed no effect of genotype on velocity (F(1, 20)= 2.883; p = .105).
Similarly, 12-month-old HEM mice needed more time to reach the
platform and concurrently travelled a longer distance compared to WT
littermates (Fig. 1). Genotype had a significant effect on path length (F
(1, 20)= 18.647; p = .000) and escape latency (F(1, 20)= 18.525; p
= .000). The interaction between genotype and trials was not sig-
nificant for path length (F(7, 140)= 2.023; p =.056) and escape la-
tency (F(7; 140)= 1.874; p = .078). Hence, the results show that old
HEMs are definitely inferior in maze performance compared to old WTs,
yet the profile of their learning curve is quite similar. Again, the results
cannot be explained by differences in swim velocity (F(1, 20)= .334;
p= .570).
Remarkably, no genotype-related differences could be demonstrated
in the probe trial, even though the learning curves significantly differed
between HEM and WT animals of 6 and 12 months of age. In spite of
non-significance, 12-month-old HEM animals tend to spend less time in
the target quadrant (p=0.075), as can be visually observed in Fig. 1.
An age-related effect for quadrant preference was observed. Here, 12-
month-old mice spent significantly more time in the opposite quadrant
compared to 6-month-old mice (t = −2.723; p= .009), indicating an
altered searching pattern at old age.
Analyses of variance indicated that there were significant differ-
ences between the time spent in each quadrant (p < 0.005). Tukey
post-hoc analyses always revealed significant differences between the
time spent in the target quadrant and the opposite quadrant, except in
3-month-old and 12-month-old hemizygous mice. In all other groups,
the time in the target quadrant always significantly differed from the
time in the opposite quadrant and at least one other adjacent quadrant.
Therefore, we believe that the animals definitely have an existent
memory of the platform position. Remarkably, only 12-month-old
hemizygous mice have no specific preference for any quadrant, given
the lack of significant differences in time between all the different
quadrants. This finding suggest that memory is severely affected in
hemizygous mice of 12 months of age.
3.2. Cage activity hints towards hyperactivity during the dark phase
During the polysomnographic recordings, ambulatory cage activity
was tracked using infrared sensors. To ensure decent habituation of the
animals, only the third day of recording was included in the analysis
(similar to the sleep analyses). We found that, at all ages, both geno-
types exhibited a higher activity level in the dark period, the animal’s
active phase, than in the light phase (t = −12.957; p= .000).
We divided every 12 h light/dark block into smaller blocks of 6 h,
resulting in 4 main time blocks: L1 (08:00-14:00), L2 (14:00-20:00), D1
(20:00-02:00) and D2 (02:00-08:00). The total light phase was in-
dicated as ‘L’, the total dark phase as ‘D’. An overall aging effect was
present (F(2, 36)= 5.315; p= 0.009)., which was most noticeable in
the light phase (L: F (2, 47) = 5.725; p= .006, L1: F (2, 48) = 5.254;
p= .009, L2: F (2, 48) = 5.491; p= .007). The cage activity plots
(Fig. 2) demonstrated that WT animals had a high cage activity level at
three months, which gradually decreased with aging, while HEM mice
had a similar activity profile at 3 and 6 months and became hyperactive
in the dark phase at 12 months of age. Evidently, 12-month-old HEM
APP23 mice were significantly more active than WT littermates during
the D1 phase (t = −3.534; p= .003) and the whole dark phase (t =
−2.484; p= .029). Additionally, a significant difference was observed
in the D1 phase of 3-month-old mice (t = -2.442; p= .028), which is
due to the fact that young WT mice are more active during the first part
of the night than HEM mice. Independent samples t-test identified no
significant genotype differences at 6 months of age. Hence, ambulatory
cage activity is affected at an old age, at which HEM APP23 mice seem
to be hyperaroused or hyperactive in the dark phase. Reversely, at a
young age, WT mice appear to be more active than HEM mice.
3.3. Sleep architecture is affected at an older age but only during the dark
phase
Polysomnographic data allowed us to quantify the total amount of
time the mice spent awake or in NREM and REM sleep during the light
and dark phase, as well as the average episode/bout duration. All mice
displayed a preference for sleep during the light phase (NREM: F(1,
59)= 429.880; p= .000, REM: (F(1, 59) = 863.019; p= .000, wake:
(F(1, 59) = 1536.032; p= .000). Also, average episode duration of all
vigilance stages was significantly dependent on the light-dark cycle
(NREM: F(1, 59) = 203.673; p= .000, REM: (F(1, 59) = 11.286;
p= .001, wake: (F(1, 59) = 90.157; p= .000).
In both WT and HEM APP23 mice, the sleep-wake architecture
undergoes changes with aging. Bout duration of all vigilance states
significantly differs during the course of aging (NREM: F(2,
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Fig. 1. Morris water maze performance of APP23 mice is affected at 6 months of age. Path length (A) and escape latency (B) of hemizygous (HEM) APP23 mice
(closed symbols) and wild-type (WT) littermates (open symbols) during acquisition trial blocks in the hidden-platform MWM experiment at 3 (WT: n=10, HEM:
n=11), 6 (WT: n=12, HEM: n=10) and 12 months (WT: n=11, HEM: n=11) of age. Also, the time spent in each quadrant during probe trial is shown (C).
Asterisks indicate significant genotype difference as assessed by post-hoc independent samples Student’s t-test; *p < 0.05, **p < 0.01.
Fig. 2. Ambulatory cage activity demonstrates that HEM APP23 mice are hyperactive at old age. Cage activity profile of the last 24 h of the polysomnographic
recording in (A) 3-month-old (WT: n=10, HEM: n=9), (B) 6-month-old (WT: n=11, HEM: n=10) and (C) 12-month-old (WT: n=11, HEM: n=11) mice. Bars
represent mean (± SEM) summed number of beam crossings within a 30-minute interval. Shaded background represents the dark active phase of the animals’ 12 h/
12 h day/night cycle (lights on at 8 a.m.).
J. Van Erum, et al. Behavioural Brain Research 373 (2019) 112089
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59)= 72.895; p= .000, REM: (F(2, 59) = 6.141; p= .001, wake: (F(2,
59) = 5.209; p= .000) (Table 1). Concurrently, age had an effect on
the total wake time (F(2, 59)= 33.519; p= .000) and the total time
spent in NREM (F(2, 59) = 35.968; p= .000). By contrast, REM sleep
stays relatively well conserved F(2, 59) = 2.112; p= .130). Young 3-
month-old mice were awake during about 63% of the day. At 6 months
of age, wakefulness gradually decreased, but increased again at an older
age of 12 months. Moreover, the difference in total wake duration be-
tween the light and dark phase (phase x age interaction) was most
noticeable at the age of 6 months (F(2, 59) = 9.864; p= .000).
Mixed design ANOVA revealed genotype differences in total NREM
time (F(1, 59)= 12.276; p= .001) and total wake time (F(1, 59) =
14.456; p= .000), and in wake bout duration (F(1, 59) = 4.723; p=
.034). Also, the difference in time awake (F(1, 59) = 7.998; p= .006)
and wake bout duration (F(1, 59) = 5.463; p= .023) between light
and dark phase were more pronounced in HEM APP23 mice. Post-hoc
independent samples t-test unveiled that 3-month-old HEM APP23 mice
are slightly more awake than WT littermates, even though this differ-
ence was only borderline significant (t = −2.119; p= .047). More
pronounced genotype differences were found at the older age of 12
months. At this stage of pathology, total NREM (t=2.713; p= .013),
REM (t=2.542; p= .019), and wake (t = −3.161; p= .005) time
were all significantly affected. Remarkably, these differences were a
result of disturbed sleep patterns during the dark phase alone. NREM
and REM sleep was decreased during the dark phase by respectively
35% and 55% (NREM: t=5.093; p= .000, REM: t=5.405; p= .000),
while wakefulness was increased by 16% (t = −5.896; p= .000)
(Fig. 3). Additionally, 12-month-old HEM mice displayed significant
longer wake episodes during the dark phase (t = −2.297; p= .033)
(Table 1). In the light phase, no genotype-related differences could be
observed.
However, we observed that in the light phase (L), which was further
subdivided into L1 (08:00–14:00) and L2 (14:00–20:00), sleep was
significantly more fragmented in 6-month-old (L: t = −3.692; p=
.002, L1: t = −4.094; p= .001, L2: t = −2.224; p= .039) and 12-
month-old (L: t = −2.622; p= .019, L1: t = −2.719; p= .015, L2: t
= −2.180; p= .045) HEM mice. Thus, sleep fragmentation already
occurred at 6 months of age, and appeared much earlier than quanti-
tative changes in sleep. Sleep fragmentation was also more pronounced
in the L1 phase than in the L2 phase.
To investigate the relationship between sleep and cognition,
Pearson correlation between MWM performance and sleep was calcu-
lated. Total sleep time (total NREM and REM time combined) sig-
nificantly inversely correlated with learning disability, defined as the
path length on trial 8 (r = −0.417, n = 65, p= 0.001).
3.4. Spectral power of brain oscillatory activity in APP23 mice is shifted
towards higher frequencies
Quantitative EEG measures are increasingly considered as a poten-
tial biomarker for AD. In AD patients, a slowing of the EEG during
wakefulness and REM has been demonstrated [31,32]. By contrast, not
many transgenic models mimic these features. Therefore, we de-
termined spectral EEG power for all three different vigilance states, in
order to characterize the brain oscillatory activity of the APP23 model.
In this analysis, we focus on the parietal EEG, since frontal EEG
might contain artifacts such as chewing and ocular contamination. At 3
months, almost no genotype differences in parietal EEG power were
found. Differences in power spectra in wake and NREM only arose from
6 months of age. In wake, delta power was decreased (t=3.765; p=
Table 1
Average wake episode duration is longer during the dark phase at 12 months of age in APP23 mice.
3M 6M 12M
WT (n=10) HEM (n=11) WT (n= 12) HEM (n=10) WT (n= 11) HEM (n=11)
NREM BD Light 153.4 ± 17.2 160.10 ± 10.9 252.1 ± 9.3 225.5 ± 12.1 159.9 ± 12.3 172.1 ± 16.3
Dark 64.6 ± 3.8 54.7 ± 6.5 179.5 ± 6.4 172.3 ± 9.0 111.8 ± 8.3 95.0 ± 7.7
Total 139.3 ± 14.6 147.5 ± 11.8 224.9 ± 7.3 208.7 ± 11.0 139.4 ± 10.3 143.8 ± 12.8
REM BD Light 76.0 ± 5.5 71.2 ± 4.2 73.0 ± 2.6 80.09 ± 2.4 82.7 ± 3.6 83.8 ± 3.0
Dark 60.6 ± 2.4 64.2 ± 4.6 66.5 ± 4.5 74.6 ± 5.8 74.3 ± 4.7 78.5 ± 7.3
Total 71.9 ± 4.2 69.5 ± 3.8 71.7 ± 2.4 78.3 ± 2.2 80.0 ± 3.4 81.8 ± 2.6
Wake BD Light 182.7 ± 26.1 211.9 ± 26.0 218.3 ± 15.9 196.2 ± 19.9 186.1 ± 18.3 198.1 ± 24.4
Dark 669.8 ± 83.7 1049.9 ± 234.4 639.1 ± 80.9 818.3 ± 167.3 351.0 ± 37.7* 511.6 ± 58.9
Total 353.5 ± 49.1 438.6 ± 61.7 404.2 ± 35.6 408.2 ± 43.0 261.7 ± 24.0 328.0 ± 36.3
Bout duration (BD) during the dark-light phase for every included group. At 12 months of age (12M), hemizygous (HEM) APP23 mice had longer waking episodes in
the dark phase than wild-type (WT) littermates, thereby confirming a probable hyperactive state during this period. At other stages of pathology (3M and 6M) no
significant differences were found. Data are presented as mean ± SEM. Genotype differences were assessed with an independent samples Student’s t-test (* p-
value< 0.05).
Fig. 3. Sleep architecture majorly deteriorates from 12 months of age in APP23 mice. The average time wild-type (WT) and hemizygous (HEM) APP23 mice
spent in each vigilance state ((A) NREM, (B) REM and (C) wake) at different stages of pathology (3M WT: n=10, 3M HEM: n=11, 6M WT: n=12, 6M HEM:
n=10, 12M WT: n=11, 12M HEM: n=11) throughout the light-dark phase. Bars represent mean (± SEM) time spent in the indicated vigilance state.
Additionally, the number of brief awakenings during the light phase (LTot), divided into 2 period blocks of 6 h (L1 and L2), is displayed (D).
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.002), while alpha (t = −2.920; p= .011) and beta power (t =
−3.190; p= .007) were increased in HEM APP23 mice of 6 months. At
12 months, delta (t = −2.659; p= .017) and theta (t = −2.241; p=
.040) power were decreased, while alpha (t = -2.980; p= .009) and
beta (t = −5.188; p= .000) power were increased. Thus, in wake,
parietal EEG power progressively shifts with age. In NREM sleep, delta
power was decreased while beta power was increased in 6-month-old
(delta: t=2.560; p= .023; beta: t = −3.832; p= .002) and 12-
month-old mice (delta: t=2.802; p= .013; beta: t = −2.765; p=
.014). In REM sleep, EEG power was relatively well conserved between
genotypes across aging. Only at 12 months, beta power was sig-
nificantly elevated in HEM mice (t = −2.815; p= .012) (Fig. 4).
Remarkably, only WT animals displayed a shift in oscillatory brain
activity with age. Alpha and beta activity shifted during wake, with less
alpha (F(2,23)= 7.415; p= 0.003) and beta (F(2,23) = 5.299; p=
0.013) power with increasing age. During NREM sleep, only beta ac-
tivity decreased (F(2,23) = 7.421; p= 0.003). No age-related differ-
ences could be observed during REM sleep. By consequence, the gen-
otype differences in spectral power at later ages are also partly caused
by the shift towards slower oscillations in WT animals, that is absent in
hemizygous animals (Fig. 4).
Furthermore, we observed a fronto-parietal gradient in delta power
during NREM sleep that differed with age and genotype (Fig. 5). At a
young age of 3 months, there was a frontal predominance of low fre-
quency (0.5–4 Hz) delta power during NREM, since the fronto-parietal
ratio was above 100%, confirming previous studies in rodents [33–36].
With aging, the frontal predominance disappeared (F(2, 49)= 11.698;
p= .000). Moreover, a genotype effect was present, where HEM APP23
mice have a tendency towards a reduced frontal delta predominance
during NREM. This difference was statistically significant at 6 months
of age (t = −2.236; p= .042) and borderline significant at 12 months
(t = −1.884; p= .078).
The frontal/parietal ratio of delta power during NREM sleep also
significantly correlated with the difference in path length in trial 1 and
trial 8 (r= 0.460, n = 42, p= 0.001). This suggests that frontal pre-
dominance of delta power during sleep might exert an effect on the
learning abilities of these mice.
Fig. 4. Average wake episode duration is longer during the dark phase at 12 months of age in APP23 mice. Delta (0.5–3.5 Hz), theta (3.5–7.5 Hz), alpha (7.5–12.5 Hz)
and beta (12.5–30 Hz) band power expressed relatively to the sum of all band power values (%). Data were depicted per age group (3 months: WT: n=9, HEM:
n=9; 6 months: WT: n=8, HEM: n=8; 12 months: WT: n=9, HEM: n=9) and per vigilance state (NREM, REM and wake). Genotype differences were assessed by
means of post-hoc independent samples Student’s t-test. Bars represent mean (± SEM), * p-value< 0.05.
Fig. 5. Reduced frontal predominance with aging. The ratio of relative delta
power in NREM sleep in the frontal cortex to that in parietal cortex, which
demonstrates the regional dominance of delta power during NREM sleep. Power
values above 100% indicate a frontal predominance, while power values below
that indicate a parietal dominance. The letters ‘a’ and ‘b’ indicate age-related
differences, where ‘a’ means significant different from 3-month-old (3M) wild-
type (WT) mice and ‘b’ fom 3M hemizygous (HEM) mice, as assessed by post
hoc independent samples Student’s t-test with Bonferroni correction (p <
0.0167). Genotype differences were also analyzed with post-hoc independent
samples Student’s t-test (* p-value<0.05). Bars represent mean (± SEM) delta
power during NREM sleep (3M: WT: n=9, HEM: n=9; 6M: WT: n=8, HEM:
n=8; 12M: WT: n=9, HEM: n=9).
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4. Discussion
4.1. Sleep and cognition
The APP23 amyloidosis mouse model displays severe sleep and
activity disturbances during the dark, active phase, but only at an ad-
vanced stage of pathology. Although no individual pathological as-
sessments have been included into analyses, the evolution of the pa-
thology in this model has been thoroughly characterized [19–21]. At
the onset of plaque deposition, at 6 months, already slight sleep ar-
chitectural changes could be noted, such as a more fragmented pattern.
However, no notable reduction in TST or time awake could be de-
monstrated at this stage. At 12 months of age, however, when amyloid
plaques are diffusely present in the neocortex and hippocampus, NREM
and REM sleep time were significantly reduced, while wakefulness was
significantly increased. These alterations were a result of disturbances
during the dark phase alone, suggesting a hyperaroused state during the
active phase. Cage activity recordings, wherein 12-month-old animals
also displayed hyperactivity during the dark phase, confirmed these
findings. The course of sleep architectural changes is grossly parallel to
the course of cognitive decline. Sleep fragmentation is apparent from 6
months onwards, when also MWM performance is severely affected.
When pathology advances, and cognition even further deteriorates, also
sleep function becomes progressively worse. Additionally, a correlation
was established between total TST and the ability to learn. This cor-
relation might be a direct result of amyloid pathology itself, where
amyloid causes a deterioration of both sleep and cognition. However, it
might also be a sign of a positive feedback loop at work, in which re-
duced sleep again has a negative effect on cognitive performance, since
sleep processes are presumed to participate in memory consolidation,
an active process that relies on reactivation and reorganization of newly
encoded representations [17]. Of note, sleep disturbances are a hall-
mark symptom of depression, and sleep issues also increase one’s risk
for depression [37]. Like sleep disturbances, depressive symptoms arise
early in the course of the disease [38], and both symptoms have also
been identified as possible risk factors for AD [39]. Possibly, initial Aβ
toxicity might disrupt pathways that are involved in both depression
and sleep, causing these symptoms to coincide in the prodromal stage
[40].
With aging, the TST reduces in the APP23 model. Generally, 12-
month-old mice sleep less than 6-month-old mice. By contrast, 3-
month-old mice sleep the least, although this could be a sign of the
reduced sleep time often observed during adolescence [41]. Corre-
spondingly, an age-related decline of TST has been demonstrated in
human subjects [42–44].
The sleep architecture of AD patients is more deteriorated than that
of age-matched control individuals. Already at early stages of the dis-
ease, AD patients (with a mean MMSE score around 23) have SWS re-
ductions and experience longer and more frequent nocturnal awaken-
ings [45]. With advancing severity of the disease, sleep fragmentation
and SWS reduction aggravate and co-occur with REM sleep reductions
[3,6,7,46]. Study finds that waking and REM measures are the strongest
predictors of cognitive performance. Night-time wakefulness and REM
sleep consistently predicted significant variance in cognitive and
functional status measures in a large sample of community-dwelling AD
patients [47]. APP23 mice of 6 months old exhibited a more fragmented
sleep pattern during the light phase, although reductions in sleep or
wake time could not be demonstrated yet. At this stage, cognitive
performance was already affected. At a more advanced stage (12
months), sleep fragmentation coincided with NREM and REM reduc-
tions, along with further cognitive impairment. Hence, the onset of
sleep disturbances in the APP23 model emerges quite early in the dis-
ease process. Sleep disturbances start moderately (namely with in-
creased fragmentation) but progressively worsen, ultimately with re-
ductions of SWS and REM sleep. Additionally, these sleep-wake
alterations parallel cognitive decline. In conclusion, the APP23 model
mimics the clinical situation well concerning the onset and progression
of sleep disturbances and their relation with cognitive disabilities.
Remarkably, increased wakefulness and reduced sleep time (at ad-
vanced stages of pathology) are only present during the dark (i.e. ac-
tive) phase, and not during the light phase. Together with the fact that
ambulatory cage activity is higher in the dark [48], these findings
suggest that old APP23 mice are hyperactive in their active period. This
might correspond to the sundowning phenomenon in AD patients, in
which symptoms (agitation, activity) are aggravated around dawn.
Since the sleep-wake cycle is organized in a ‘flip-flop’ system [49] and
mice exhibit a polyphasic sleep pattern, we are unable to determine
whether this disruption is caused by the dysfunction of either wake- or
sleep-promoting circuits. Either adrenergic or serotonergic branches of
the reticular activating system might be overactive, or the galaninergic
ventrolateral preoptic nucleus fails to inhibit this wake-promoting
system. Lesions of the VLPO in rodents result in marked sleep frag-
mentation and a decrease of total sleep time, similar to the observed
phenotype in the APP23 model [50]. Additionally, a study in the
Tg2576 amyloidosis model has indicated that a cholinergic deficit has
functional consequences for the EEG and for sleep regulation. Possibly,
functional loss of the VLPO and nucleus basalis contributes to sleep loss
and sleep fragmentation in both the APP23 model and AD patients [51].
Because of the polyphasic sleep pattern of mice and the uniphasic sleep
of humans, it is quite difficult to encompass the light-dark differences
within the clinical situation. Moreover, other AD mouse models do not
uniformly display an increased wakefulness during the dark phase.
Some reports indicate an increased wakefulness that is more pro-
nounced during the dark phase [52,53], others during the light phase
[16]. NREM and REM sleep was even conserved in the Tg2576 model
up to 17 months [54]. These data demonstrate the dissension between
the different models, of which the underlying cause remains currently
unknown.
4.2. Spectral EEG components and their relation with sleep function
In AD patients, an overall slowing of the EEG has been demonstrated
[31,32]. Moreover, this phenomenon has been increasingly considered
as a potential biomarker for AD. However, many transgenic AD mouse
models fail to recapitulate this EEG characteristic, since EEG slowing is
probably caused by a loss of functional connectivity between cortical
regions as a result of neurodegeneration and cholinergic deficits [32],
while these manifestations are rather limited in transgenic mice [55].
Instead, most studies in amyloidosis models report an EEG power shift
towards fast-frequency oscillations [52–54].
In the APP23 model, a similar tendency towards fast frequencies
was found. Furthermore, this spectral shift appeared to progress with
age. This progressive nature was best observed during wakefulness. At 3
months, genotype-related differences were relatively minor and only
beta power was significantly increased in HEM APP23 mice. At 6
months, delta power was decreased, while alpha and beta power were
increased. In 12-month-old HEM APP23 mice, all power bands were
significantly different from WT littermates, including the theta band.
This tendency towards fast frequencies is potentially a characteristic
specific to mouse models that present with an overload of amyloid in
the absence of neurodegeneration. What factors lie at the basis of this
network desynchronization is currently unknown. In vitro experiments
have demonstrated that Aβ can cause desynchronization of action po-
tential generation in pyramidal cells and a general shift of the balance
between excitation and inhibition in the hippocampal circuitry [56].
Recently, Aβ has been demonstrated to morphologically distort neurites
in the barrel cortex of APP/PS1 mice, which is hypothesized to disrupt
the precise temporal firing patterns in the neural network [57]. Similar
findings were reported in post-mortem AD brains, where a neuron re-
ceiving input from dendrites that traverse an Aβ deposit would take
longer to reach threshold for an action potential compared to input
from dendrites that did not traverse an Aβ deposit [58]. The induced
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curvature probably reduces the synchrony of converging inputs (jitter),
leading to increased response variability of the neuron [59]. The re-
sultant breakdown in synchronicity of timing could disrupt the func-
tional integration of memory retrieval [58]. With respect to afore-
mentioned data, additional clinical studies could be rewarding. In
contrast, PLB1-triple mice, which represent an early-stage phenotype,
display an age-dependent shift towards lower frequencies, as opposed
to our findings [60]. This model demonstrates that the presence of
subtle amyloid and tau pathology is sufficient to cause changes in sleep
architecture and EEG spectra. However, the impact of the triple mu-
tation and the tau pathology may not be underestimated, and therefore
it proves difficult to translate these findings to the APP23 model.
A more desynchronous state during wakefulness in HEM APP23
mice might also indicate that these mice are more exploring when
awake, while the WT littermates are more quiescent. It has been de-
monstrated that APP23 mice are more agitated and exploratory from a
young age [61,62]. However, differences in cage activity patterns could
only be demonstrated at the age of 12 months, while spectral differ-
ences were already obvious at 6 months. The observed decrease of delta
power during wakefulness from 6 months of age might also be reflected
on the sleep-wake function of the animal. Waking delta power is often
considered to be a marker of sleep pressure [63]. Therefore, sleep
fragmentation, and reduced sleep time at an older age, might be a result
of the mice being less ‘sleepy’. Moreover, NREM delta power, a pro-
posed marker for sleep intensity, was also significantly lower. Less in-
tense and less deep sleep results in faster awakenings. Hence, a more
fragmented sleep pattern in HEM APP23 mice is possibly attributed to a
reduced sleep propensity (and intensity), as suggested by a reduced
delta power during wakefulness and NREM sleep. Recent studies in the
APPswe/PSEN1dE9 model confirm these findings, and demonstrate an
overall reduction of delta and theta power during NREM sleep [64,65].
Kent et al. reported no significant changes in total sleep time in this
APP/PS1 model at the age of 12 months [64]. However, in depth
analyses with separation of the light-dark photoperiod, revealed that
these mice were more awake during the dark period and more asleep
during the light period from 6 months, according to Zhang and others
[65]. Therefore, the reduced delta power may also predict a disrupted
sleep quality in this mouse model.
Remarkably, REM sleep power spectra stay relatively well con-
served in the APP23 model. Although REM time is reduced by 55% at
old age, the underlying neuronal firing appears grossly similar. Only
beta power increased significantly. In accordance, Kent et al. could not
demonstrate differences in the EEG spectra of REM sleep, while an
obvious shift towards faster oscillations was present in both wake and
NREM sleep in the APP/PS1 model [64]. By contrast, Zhang et al.
showed a reduction of delta in theta power in REM spectra, similar to
that observed during NREM sleep [65].
Since we observed spectral differences between frontal and parietal
EEG leads, we scrutinized these differences by analyzing the power
ratio between these two regions. In-depth analyses revealed that, at a
young age, there is a frontal predominance of relative delta power,
which disappeared with age. Most notably, HEM mice had a tendency
towards a reduced fronto-parietal ratio. In human subjects, the fronto-
occipital gradient decreases with age [66]. Additionally, in healthy
aged volunteers, delta power is dominant in the parietal regions [66].
According to human imaging studies, delta activity covaried negatively
with regional cerebral blood flow (rCBF) and a decrease of rCBF in
frontal regions might be associated with cortical arousal attenuation
during sleep [67]. Thus, the diminished frontal predominance of delta
activity can possibly be interpreted as an ‘alleviated dampening’ of
cortical arousal during sleep, accounting for the increased sleep frag-
mentation observed in the model [68].
In healthy, elderly humans significant associations were found be-
tween NREM frontal delta power and task performance. Delta power in
sleep was found to be positively linked to waking cerebral metabolic
rate [69]. The significant correlation between an age-dependent decline
of the NREM delta frontal/parietal gradient with the difference in path
length in trial 1 and trial 8 suggests that frontal predominance of delta
power during sleep might exert an effect on awake learning abilities.
To conclude, sleep disturbances in the APP23 mouse model manifest
at the onset of cognitive deterioration. Initially, these sleep dis-
turbances are mild. Sleep is more fragmented but abnormalities in TST
have not emerged yet. When cognitive abilities deteriorate even fur-
ther, sleep disturbances also progressively worsen, as was demonstrated
by the loss of NREM and REM sleep at the age of 12 months. Cage
activity recordings indicate that the quantitative reductions of sleep are
probably due to a hyperaroused or agitated state during the dark phase
at this age. However, along with more subtle sleep architectural
changes such as sleep fragmentation, spectral parameters of the EEG,
which can provide information about sleep quality, are changed long
before these quantitative sleep reductions arise. Hence, before sleep
time is quantitatively reduced, the quality of sleep is probably already
affected. All together, the APP23 mouse model mimics the clinical si-
tuation well, and will therefore be valid for use in the development of
sleep therapeutics for people with AD.
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